Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Total
Stockholders' Equity, Beginning Balance at Dec. 31, 2021	$ 38	$ 442,259	$ (138)	$ (347,104)	$ 95,055
Shares, Outstanding, Beginning Balance at Dec. 31, 2021	37,918,395
Exercises of vested stock options		12			12
Exercises of vested stock options (in shares)	11,484
Vesting of restricted stock units (in shares)	312,090
Stock based compensation expense		2,268			2,268
Unrealized gain (loss) on available-for-sale securities, net of tax			(85)		(85)
Net income (loss)				(21,319)	(21,319)
Stockholders' Equity, Ending Balance at Mar. 31, 2022	$ 38	444,539	(223)	(368,423)	75,931
Shares, Outstanding, Ending Balance at Mar. 31, 2022	38,241,969
Stockholders' Equity, Beginning Balance at Dec. 31, 2021	$ 38	442,259	(138)	(347,104)	95,055
Shares, Outstanding, Beginning Balance at Dec. 31, 2021	37,918,395
Unrealized gain (loss) on available-for-sale securities, net of tax					(199)
Net income (loss)					(22,782)
Stockholders' Equity, Ending Balance at Sep. 30, 2022	$ 38	450,008	(337)	(369,886)	79,823
Shares, Outstanding, Ending Balance at Sep. 30, 2022	38,520,336
Stockholders' Equity, Beginning Balance at Mar. 31, 2022	$ 38	444,539	(223)	(368,423)	75,931
Shares, Outstanding, Beginning Balance at Mar. 31, 2022	38,241,969
Exercises of vested stock options		575			575
Exercises of vested stock options (in shares)	63,012
Vesting of restricted stock units (in shares)	32,165
Issuance of common stock under ESPP		313			313
Issuance of common stock under ESPP (in shares)	102,105
Stock based compensation expense		2,460			2,460
Unrealized gain (loss) on available-for-sale securities, net of tax			(141)		(141)
Net income (loss)				(19,087)	(19,087)
Stockholders' Equity, Ending Balance at Jun. 30, 2022	$ 38	447,887	(364)	(387,510)	60,051
Shares, Outstanding, Ending Balance at Jun. 30, 2022	38,439,251
Exercises of vested stock options		15			15
Exercises of vested stock options (in shares)	5,341
Vesting of restricted stock units (in shares)	75,744
Stock based compensation expense		2,106			2,106
Unrealized gain (loss) on available-for-sale securities, net of tax			27		27
Net income (loss)				17,624	17,624
Stockholders' Equity, Ending Balance at Sep. 30, 2022	$ 38	450,008	(337)	(369,886)	79,823
Shares, Outstanding, Ending Balance at Sep. 30, 2022	38,520,336
Stockholders' Equity, Beginning Balance at Dec. 31, 2022	$ 38	452,713	(219)	(393,512)	59,020
Shares, Outstanding, Beginning Balance at Dec. 31, 2022	38,613,891
Exercises of vested stock options		185			185
Exercises of vested stock options (in shares)	51,993
Vesting of restricted stock units (in shares)	374,417
Issuance of common stock in connection with the 2023 Neurocrine Collaboration Agreement	$ 5	31,116			31,121
Issuance of common stock in connection with the 2023 Neurocrine Collaboration Agreement (in shares)	4,395,588
Stock based compensation expense		2,504			2,504
Unrealized gain (loss) on available-for-sale securities, net of tax			87		87
Net income (loss)				124,044	124,044
Stockholders' Equity, Ending Balance at Mar. 31, 2023	$ 43	486,518	(132)	(269,468)	216,961
Shares, Outstanding, Ending Balance at Mar. 31, 2023	43,435,889
Stockholders' Equity, Beginning Balance at Dec. 31, 2022	$ 38	452,713	(219)	(393,512)	$ 59,020
Shares, Outstanding, Beginning Balance at Dec. 31, 2022	38,613,891
Exercises of vested stock options (in shares)					377,593
Unrealized gain (loss) on available-for-sale securities, net of tax					$ (29)
Net income (loss)					75,935
Stockholders' Equity, Ending Balance at Sep. 30, 2023	$ 44	494,001	(248)	(317,577)	176,220
Shares, Outstanding, Ending Balance at Sep. 30, 2023	43,909,161
Stockholders' Equity, Beginning Balance at Mar. 31, 2023	$ 43	486,518	(132)	(269,468)	216,961
Shares, Outstanding, Beginning Balance at Mar. 31, 2023	43,435,889
Exercises of vested stock options	$ 1	1,228			1,229
Exercises of vested stock options (in shares)	198,348
Vesting of restricted stock units (in shares)	62,828
Issuance of common stock under ESPP		418			418
Issuance of common stock under ESPP (in shares)	62,344
Stock based compensation expense		2,627			2,627
Unrealized gain (loss) on available-for-sale securities, net of tax			(1)		(1)
Net income (loss)				(22,208)	(22,208)
Stockholders' Equity, Ending Balance at Jun. 30, 2023	$ 44	490,791	(133)	(291,676)	199,026
Shares, Outstanding, Ending Balance at Jun. 30, 2023	43,759,409
Exercises of vested stock options		415			415
Exercises of vested stock options (in shares)	127,252
Vesting of restricted stock units (in shares)	22,500
Stock based compensation expense		2,795			2,795
Unrealized gain (loss) on available-for-sale securities, net of tax			(115)		(115)
Net income (loss)				(25,901)	(25,901)
Stockholders' Equity, Ending Balance at Sep. 30, 2023	$ 44	$ 494,001	$ (248)	$ (317,577)	$ 176,220
Shares, Outstanding, Ending Balance at Sep. 30, 2023	43,909,161